US › Healthcare

VistaGen Therapeutics Inc (VTGN)

US · Healthcare · Biotechnology

$0.20-4.76%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

+504.9%

Net profit

$-13.0M

EPS

$-0.30

EPS estimate

$-0.29

Net margin

-882.8%

EPS came in at -0.30 against a street estimate of -0.29 — a miss of 3.4%.

Key statistics

Market cap

$8.9M

Forward P/E

0.0

P/B

0.66

Book value

$0.55

EPS (TTM)

$-1.66

52-week high

$5.14

52-week low

$0.20

50-day MA

$0.25

200-day MA

$0.47

Beta

0.33

Analyst view

Analysts rate VistaGen Therapeutics Inc a hold (0 buy, 4 hold, 0 sell out of 4) with an average price target of $1.00.

Shareholding

Insiders

0.37%

Institutions

31.05%

Largest institutional holders

Fund	Stake
COMMODORE CAPITAL LP	6.28%
Vanguard Capital Management, LLC	3.55%
Two Sigma Investments LLC	1.91%
Acadian Asset Management LLC	1.79%
Renaissance Technologies Corp	1.65%
StemPoint Capital LP	1.39%
Ikarian Capital, LLC	1.17%
AdvisorShares Investments, LLC	0.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for VistaGen Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.